FRONT PAGE AMPYRA AUBAGIO AVONEX BETASERON COPAXONE EXTAVIA
Stan's Angels MS News Channel on YouTube GILENYA NOVANTRONE REBIF RITUXAN TECFIDERA TYSABRI
 Daily News for Neuros, Nurses & Savvy MSers: 208,152 Viewers, 8,368 Stories & Studies
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
CLICK ON THE RED BUTTON BELOW
You'll get FREE Breaking News Alerts on new MS treatments as they are approved
MS NEWS ARCHIVES: by week

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
and
Medical Director-Rocky Mountain MS Center


Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an M.D....my Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore


This page is powered by Blogger. Isn't yours?

Tuesday

 

GIFT15 for RRMS
































Image Source: LOOKFORDIAGNOSIS

GIFT15 is an experimental treatment for MS. It is composed of two proteins fused together — granulocyte macrophage-colony stimulating factor (GSM-CSF) and interleukin-15 (IL-15). Alone, each component stimulates innate and adaptive immunity. Fused together, they suppress it.

The potential of this treatment in humans has only begun to be considered, but GIFT15 has completely reversed experimental allergic encephalomyelitis (EAE) in laboratory mice. It was developed by researchers at the Jewish General Hospital Lady Davis Institute for Medical Research and McGill University in Montreal.

Allergic encephalitis evolution in mice is similar to MS in humans. For the study, the researchers took B-cells from the EAE mice, purified them, put them in a petri dish, and then sprinkled the B-cells with GIFT15. When they injected the B-cells back into the sick mice, the disease disappeared — T-cells were blocked, inflammation in the spinal cord stopped, and the mice recovered within four weeks of treatment.

Scientists believe that the success of fusing the pharmacological properties of GSM-CSF and IL-15 introduce a promising strategy for generating other cellular pharmaceuticals into treatments for MS and other autoimmune diseases. Mixing biologically active proteins in an unnatural manner may be a strategy that confuses the natural path of disease. Additionally, because the strategy employs the patient’s own cells, the treatment would likely not bring about an immune response leading to rejection.

Clinical studies are still needed to test GIFT15 safety and effectiveness in humans.

Story Source: The above story is based on materials provided by MULTIPLESCLEROSISNEWSTODAY
Note: Materials may be edited for content and length


Go to Newer News Go to Older News